EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion

Linyong Du, Zhipeng Su, Silu Wang, Ying Meng, Fei Xiao, Daqian Xu, Xinjian Li, Xu Qian, Su Bin Lee, Jong-Ho Lee, Zhimin Lu iD, Jianxin Lyu

Advanced Science · 2023-09 · 10 (27)

DOI: 10.1002/advs.202206380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.08.2023. Verfasst von Linyong Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Science, Wenzhou Medical University, We…. Hauptthemen laut MEDLINE: CD47 Antigen, Glioblastoma, Tumor Escape. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, Zhejiang Natural Science Foundation-Key Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor cells often overexpress immune checkpoint proteins, including CD47, for immune evasion. However, whether or how oncogenic activation of receptor tyrosine kinases, which are crucial drivers in tumor development, regulates CD47 expression is unknown. Here, it is demonstrated that epidermal growth factor receptor (EGFR) activation induces CD47 expression by increasing the binding of c‐Src to CD47, leading to c‐Src‐mediated CD47 Y288 phosphorylation. This phosphorylation inhibits the interaction between the ubiquitin E3 ligase TRIM21 and CD47, thereby abrogating TRIM21‐mediated CD47 K99/102 polyubiquitylation and CD47 degradation. Knock‐in expression of CD47 Y288F reduces CD47 expression, increases macrophage phagocytosis of tumor cells, and inhibits brain tumor growth in mice. In contrast, knock‐in expression of CD47 K99/102R elicits the opposite effects compared to CD47 Y288F expression. Importantly, CD47‐SIRPα blockade with an anti‐CD47 antibody treatment significantly enhances EGFR‐targeted cancer therapy. In addition, CD47 expression levels in human glioblastoma (GBM) specimens correlate with EGFR and c‐Src activation and aggravation of human GBM. These findings elucidate a novel mechanism underlying CD47 upregulation in EGFR‐activated tumor cells and underscore the role of the EGFR‐c‐Src‐TRIM21‐CD47 signaling axis in tumor evasion and the potential to improve the current cancer therapy with a combination of CD47 blockade with EGFR‐targeted remedy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenGlioblastomaTumor EscapeAnimalsHumansMiceCell Line, TumorErbB ReceptorsPhosphorylation

Stichwörter der Autor:innen

CD47TRIM21c-Srcepidermal growth factor receptorimmune evasionpolyubiquitylationtumor cells

Substanzen

CD47 AntigenCD47 protein, humanEGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Key Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
  • Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University Wenzhou, Zhejiang, 325000, China.
  • Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, Ch…
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease of The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310029, Ch…
  • Cancer Center, Zhejiang University, Hangzhou, Zhejiang, 310029, China.
  • CAS Key Laboratory of Infection and Immunity, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.

ORCID-Profile: Zhimin Lu

Förderung

  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Zhejiang Natural Science Foundation-Key Project
  • Zhejiang Natural Science Foundation Grant
  • Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang
  • Zhejiang University Research Fund
  • Key Discipline of Zhejiang Province in Public Health and Preventive Medicine (First Class, Category A) in Hangzhou Medical College
  • National Research Foundation of Korea (NRF) grant funded by the Korean government

Zitieren

APA

Du, L., Su, Z., Wang, S., Meng, Y., Xiao, F., Xu, D., Li, X., Qian, X., Lee, S. B., Lee, J. H., Lu, Z., & Lyu, J. (2023). EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion. Advanced Science, 10(27). https://doi.org/10.1002/advs.202206380

Vancouver

Du L, Su Z, Wang S, Meng Y, Xiao F, Xu D, et al. EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion. Advanced Science. 2023;10(27). doi:10.1002/advs.202206380

BibTeX
@article{Du2023,
  author = {Du, Linyong and Su, Zhipeng and Wang, Silu and Meng, Ying and Xiao, Fei and Xu, Daqian and Li, Xinjian and Qian, Xu and Lee, Su Bin and Lee, Jong-Ho and Lu, Zhimin and Lyu, Jianxin},
  title = {EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {27},
  doi = {10.1002/advs.202206380}
}
Kostenlos starten →